AstraZeneca Retains 90% Of GI Business Despite Prilosec Generics
• By The Pink Sheet
AstraZeneca is retaining 90% of its gastrointestinal business through increased use of the proton pump inhibitor Nexium, despite the availability of generic Prilosec in the U.S., CEO Tom McKillop said July 24
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
